Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients
Viral infections and reactivations are major causes of morbidity and mortality after hematopoietic stem cell (HSCT) and solid organ transplantation (SOT) as well as in patients with immunodeficiencies. Latent herpesviruses (e.g., cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6), lytic v...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015970/ https://www.ncbi.nlm.nih.gov/pubmed/34989946 http://dx.doi.org/10.1007/s10875-021-01205-1 |
_version_ | 1784688427613028352 |
---|---|
author | Schulze Lammers, Friederike C. Bonifacius, Agnes Tischer-Zimmermann, Sabine Goudeva, Lilia Martens, Jörg Lepenies, Bernd von Karpowitz, Maria Einecke, Gunilla Beutel, Gernot Skripuletz, Thomas Blasczyk, Rainer Beier, Rita Maecker-Kolhoff, Britta Eiz-Vesper, Britta |
author_facet | Schulze Lammers, Friederike C. Bonifacius, Agnes Tischer-Zimmermann, Sabine Goudeva, Lilia Martens, Jörg Lepenies, Bernd von Karpowitz, Maria Einecke, Gunilla Beutel, Gernot Skripuletz, Thomas Blasczyk, Rainer Beier, Rita Maecker-Kolhoff, Britta Eiz-Vesper, Britta |
author_sort | Schulze Lammers, Friederike C. |
collection | PubMed |
description | Viral infections and reactivations are major causes of morbidity and mortality after hematopoietic stem cell (HSCT) and solid organ transplantation (SOT) as well as in patients with immunodeficiencies. Latent herpesviruses (e.g., cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6), lytic viruses (e.g., adenovirus), and polyomaviruses (e.g., BK virus, JC virus) can cause severe complications. Antiviral drugs form the mainstay of treatment for viral infections and reactivations after transplantation, but they have side effects and cannot achieve complete viral clearance without prior reconstitution of functional antiviral T-cell immunity. The aim of this study was to establish normal ranges for virus-specific T-cell (VST) frequencies in healthy donors. Such data are needed for better interpretation of VST frequencies observed in immunocompromised patients. Therefore, we measured the frequencies of VSTs against 23 viral protein-derived peptide pools from 11 clinically relevant human viruses in blood from healthy donors (n = 151). Specifically, we determined the VST frequencies by interferon-gamma enzyme-linked immunospot assay and classified their distribution according to age and gender to allow for a more specific evaluation and prediction of antiviral immune responses. The reference values established here provide an invaluable tool for immune response evaluation, intensity of therapeutic drugs and treatment decision-making in immunosuppressed patients. This data should make an important contribution to improving the assessment of immune responses in immunocompromised patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10875-021-01205-1. |
format | Online Article Text |
id | pubmed-9015970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-90159702022-05-02 Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients Schulze Lammers, Friederike C. Bonifacius, Agnes Tischer-Zimmermann, Sabine Goudeva, Lilia Martens, Jörg Lepenies, Bernd von Karpowitz, Maria Einecke, Gunilla Beutel, Gernot Skripuletz, Thomas Blasczyk, Rainer Beier, Rita Maecker-Kolhoff, Britta Eiz-Vesper, Britta J Clin Immunol Original Article Viral infections and reactivations are major causes of morbidity and mortality after hematopoietic stem cell (HSCT) and solid organ transplantation (SOT) as well as in patients with immunodeficiencies. Latent herpesviruses (e.g., cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6), lytic viruses (e.g., adenovirus), and polyomaviruses (e.g., BK virus, JC virus) can cause severe complications. Antiviral drugs form the mainstay of treatment for viral infections and reactivations after transplantation, but they have side effects and cannot achieve complete viral clearance without prior reconstitution of functional antiviral T-cell immunity. The aim of this study was to establish normal ranges for virus-specific T-cell (VST) frequencies in healthy donors. Such data are needed for better interpretation of VST frequencies observed in immunocompromised patients. Therefore, we measured the frequencies of VSTs against 23 viral protein-derived peptide pools from 11 clinically relevant human viruses in blood from healthy donors (n = 151). Specifically, we determined the VST frequencies by interferon-gamma enzyme-linked immunospot assay and classified their distribution according to age and gender to allow for a more specific evaluation and prediction of antiviral immune responses. The reference values established here provide an invaluable tool for immune response evaluation, intensity of therapeutic drugs and treatment decision-making in immunosuppressed patients. This data should make an important contribution to improving the assessment of immune responses in immunocompromised patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10875-021-01205-1. Springer US 2022-01-06 2022 /pmc/articles/PMC9015970/ /pubmed/34989946 http://dx.doi.org/10.1007/s10875-021-01205-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Schulze Lammers, Friederike C. Bonifacius, Agnes Tischer-Zimmermann, Sabine Goudeva, Lilia Martens, Jörg Lepenies, Bernd von Karpowitz, Maria Einecke, Gunilla Beutel, Gernot Skripuletz, Thomas Blasczyk, Rainer Beier, Rita Maecker-Kolhoff, Britta Eiz-Vesper, Britta Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients |
title | Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients |
title_full | Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients |
title_fullStr | Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients |
title_full_unstemmed | Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients |
title_short | Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients |
title_sort | antiviral t-cell frequencies in a healthy population: reference values for evaluating antiviral immune cell profiles in immunocompromised patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015970/ https://www.ncbi.nlm.nih.gov/pubmed/34989946 http://dx.doi.org/10.1007/s10875-021-01205-1 |
work_keys_str_mv | AT schulzelammersfriederikec antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT bonifaciusagnes antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT tischerzimmermannsabine antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT goudevalilia antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT martensjorg antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT lepeniesbernd antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT vonkarpowitzmaria antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT eineckegunilla antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT beutelgernot antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT skripuletzthomas antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT blasczykrainer antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT beierrita antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT maeckerkolhoffbritta antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients AT eizvesperbritta antiviraltcellfrequenciesinahealthypopulationreferencevaluesforevaluatingantiviralimmunecellprofilesinimmunocompromisedpatients |